DE69735942D1 - Neuartige inhibitoren der aktivität des wachstumsfaktors für gefäss-endothelzellen (vegf), ihre verwendungen und verfahren zu ihrer herstellung - Google Patents

Neuartige inhibitoren der aktivität des wachstumsfaktors für gefäss-endothelzellen (vegf), ihre verwendungen und verfahren zu ihrer herstellung

Info

Publication number
DE69735942D1
DE69735942D1 DE69735942T DE69735942T DE69735942D1 DE 69735942 D1 DE69735942 D1 DE 69735942D1 DE 69735942 T DE69735942 T DE 69735942T DE 69735942 T DE69735942 T DE 69735942T DE 69735942 D1 DE69735942 D1 DE 69735942D1
Authority
DE
Germany
Prior art keywords
vegf
proteins
growth factor
activity
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69735942T
Other languages
English (en)
Other versions
DE69735942T2 (de
Inventor
Lynn Davis-Smyth
Hsifei Chen
Leonard Presta
Napoleone Ferrara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24582415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69735942(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69735942D1 publication Critical patent/DE69735942D1/de
Application granted granted Critical
Publication of DE69735942T2 publication Critical patent/DE69735942T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69735942T 1996-05-07 1997-05-06 Neuartige inhibitoren der aktivität des wachstumsfaktors für gefäss-endothelzellen (vegf), ihre verwendungen und verfahren zu ihrer herstellung Expired - Lifetime DE69735942T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/643,839 US6100071A (en) 1996-05-07 1996-05-07 Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US643839 1996-05-07
PCT/US1997/007694 WO1997044453A1 (en) 1996-05-07 1997-05-06 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production

Publications (2)

Publication Number Publication Date
DE69735942D1 true DE69735942D1 (de) 2006-06-29
DE69735942T2 DE69735942T2 (de) 2007-01-04

Family

ID=24582415

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735942T Expired - Lifetime DE69735942T2 (de) 1996-05-07 1997-05-06 Neuartige inhibitoren der aktivität des wachstumsfaktors für gefäss-endothelzellen (vegf), ihre verwendungen und verfahren zu ihrer herstellung

Country Status (11)

Country Link
US (15) US6100071A (de)
EP (4) EP2336322A1 (de)
JP (1) JP3457330B2 (de)
AT (1) ATE327327T1 (de)
AU (1) AU717112B2 (de)
CA (2) CA2253738A1 (de)
DE (1) DE69735942T2 (de)
DK (1) DK0907733T3 (de)
ES (1) ES2267143T3 (de)
NZ (1) NZ332779A (de)
WO (1) WO1997044453A1 (de)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
JPH09154588A (ja) * 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AU731927B2 (en) * 1996-11-21 2001-04-05 Kyowa Hakko Kirin Co., Ltd. Anti-human VEGF receptor F1t-1 monoclonal antibody
US6348333B1 (en) * 1997-01-17 2002-02-19 Toa Gosei Co., Ltd. VEGF-binding KDR polypeptide
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
DK1119371T3 (da) * 1998-10-09 2011-03-07 Vegenics Ltd Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU773891C (en) 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
IL142583A0 (en) * 1998-11-06 2002-03-10 Basf Ag Inhibition of the formation of vascular hyperpermeability
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
EP1553414A1 (de) * 1999-04-13 2005-07-13 Medarex, Inc. Methoden zur Diagnose und Behandlung metastasierender Prostata-Tumore
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
NZ515913A (en) * 1999-06-08 2004-01-30 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US20020142982A1 (en) * 1999-09-02 2002-10-03 Timothy Hla Method for regulating angiogenesis
GB9928950D0 (en) * 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
ATE377081T1 (de) 2000-02-25 2007-11-15 Ludwig Inst Cancer Res Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
CA2428552A1 (en) * 2000-11-28 2002-06-06 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CN1494552A (zh) 2001-01-19 2004-05-05 ·��ά��֢�о�Ժ Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
JP2005500045A (ja) * 2001-07-12 2005-01-06 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管内皮細胞材料および方法
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
AU2003215163A1 (en) * 2002-02-12 2003-09-04 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
MXPA04011470A (es) 2002-05-21 2005-02-14 Amgen Inc Compuestos heterociclicos sustituidos y metodos de uso.
JP5111729B2 (ja) * 2002-06-05 2013-01-09 ジェネンテック， インコーポレイテッド 肝成長及び肝保護のための組成物と方法
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
KR101215701B1 (ko) * 2002-07-19 2012-12-26 베스 이스라엘 데코니스 메디칼 센터 자간전증 또는 자간의 진단 및 치료 방법
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
EP2267023B1 (de) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR-Peptide und diese enthaltende Impfstoffe
US7432341B2 (en) * 2002-10-24 2008-10-07 Valo Hsj, Limited Partnership Cytokine receptor modulators and method of modulating cytokine receptor activity
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
WO2004070018A2 (en) * 2003-02-04 2004-08-19 Ludwig Institute For Cancer Research Vegf-b and pdgf modulation of stem cells
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP2006521111A (ja) 2003-03-12 2006-09-21 バスジーン セラピューティクス， インコーポレイテッド 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
US20040266688A1 (en) * 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
JP2007525187A (ja) * 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CA2519875C (en) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
US20050043235A1 (en) * 2003-06-12 2005-02-24 Kari Alitalo Use of VEGF-C or VEGF-D in reconstructive surgery
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
DK1660057T3 (da) * 2003-08-27 2012-08-20 Ophthotech Corp Kombinationsterapi til behandling af neovaskulære øjenlidelser
WO2005046602A2 (en) * 2003-11-10 2005-05-26 Greenville Hospital System Vegf receptor antagonists
US8003613B2 (en) * 2003-11-17 2011-08-23 University Of Florida Research Foundation, Inc. Methods and compositions for inducing apoptosis
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
JP4960859B2 (ja) 2004-03-12 2012-06-27 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍成長を阻害するためのポリペプチド化合物
CN102718867A (zh) 2004-03-12 2012-10-10 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
WO2005110462A2 (en) * 2004-05-04 2005-11-24 Children's Medical Center Corporation Methods and compositions for treatment of preeclampsia
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
AU2005245896A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
CN1304427C (zh) * 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
WO2005121176A1 (fr) * 2004-06-08 2005-12-22 Chengdu Kanghong Biotechnologies Co. Ltd Proteine chimerique inhibitrice d'angiogenese et utilisation associee
EP1753442A2 (de) * 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Verfahren zur verabreichung und verwendung von vegf-hemmern zur behandlung von krebs beim menschen
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
JP4944032B2 (ja) 2004-09-13 2012-05-30 ジェンザイム・コーポレーション 多量体構築物
EP1799713B1 (de) 2004-09-23 2014-11-05 VasGene Therapeutics, Inc. Polypeptidverbindungen zur hemmung von angiogenese und tumorwachstum
MX2007003522A (es) * 2004-09-24 2007-06-11 Beth Israel Hospital Complicaciones del embarazo.
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US7955805B2 (en) * 2004-12-15 2011-06-07 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing complications of pregnancy
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
US7354581B2 (en) * 2005-02-11 2008-04-08 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
PT1855707E (pt) 2005-02-28 2012-05-25 Oncotherapy Science Inc Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos
JP5737826B2 (ja) * 2005-03-11 2015-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆの阻害による貧血の処置
US20060217311A1 (en) 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7531172B2 (en) 2005-08-12 2009-05-12 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a VEGF antagonist
IL172297A (en) * 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for the diagnosis of preeclampsia
US7354582B2 (en) * 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
EP2015768A1 (de) * 2006-03-27 2009-01-21 Genentech, Inc. Verfahren zur behandlung von nierenleiden
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
AU2014201795B2 (en) * 2006-12-19 2016-05-19 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US20080248033A1 (en) 2006-12-19 2008-10-09 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US9073997B2 (en) * 2007-02-02 2015-07-07 Vegenics Pty Limited Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
EP2578684B1 (de) 2007-03-19 2016-02-24 National Research Council Of Canada Antagonisten von Liganden und ihre Verwendung
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2009023185A1 (en) 2007-08-13 2009-02-19 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
AU2008307643B9 (en) 2007-09-28 2014-04-17 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US8658135B2 (en) * 2008-03-19 2014-02-25 National Research Council Of Canada Antagonists of ligands and uses thereof
EP3192874B1 (de) 2008-06-18 2019-10-16 Oxford BioMedica (UK) Limited Virusreinigung
HUE024872T2 (en) 2008-11-22 2016-02-29 Hoffmann La Roche Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
MX2012000620A (es) 2009-07-13 2012-01-27 Genentech Inc Metodos diagnostico y composiciones para tratamiento de cancer.
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
BR112012003346A2 (pt) 2009-08-15 2016-11-16 Genentech Inc metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
CN102597776A (zh) 2009-09-11 2012-07-18 霍夫曼-拉罗奇有限公司 鉴定响应抗癌剂的可能性升高的患者的方法
MX2012002909A (es) 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CA2787952C (en) 2010-02-23 2016-07-26 Genentech, Inc. Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
CN102946907A (zh) 2010-05-28 2013-02-27 牛津生物医学（英国）有限公司 慢病毒载体向脑的递送
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
MX2013000667A (es) 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
EP2824457A1 (de) 2010-07-19 2015-01-14 F. Hoffmann-La Roche AG Verfahren zur identifizierung eines patienten mit erhöhter wahrscheinlichkeit des ansprechens auf eine antitumortherapie
ES2652508T3 (es) 2010-08-06 2018-02-02 Genzyme Corporation Composiciones de antagonistas de VEGF y sus usos
SG191334A1 (en) 2011-01-13 2013-08-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
CA2825838C (en) 2011-01-28 2020-10-27 Sanofi Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP2744508B1 (de) 2011-08-19 2017-11-08 Children's Medical Center Corporation Vegf-bindendes protein zur angiogenese-blockierung
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
RS58964B1 (sr) 2012-03-13 2019-08-30 Hoffmann La Roche Kombinovana terapija za lečenje karcinoma jajnika
SG11201407859YA (en) 2012-05-31 2014-12-30 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201500903XA (en) 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
US9106711B2 (en) 2012-09-04 2015-08-11 Telefonaktiebolaget L M Ericsson (Publ) Minimizing mapping and signaling for data path aggregation
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
US9682154B2 (en) 2013-02-04 2017-06-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
WO2014124487A1 (en) 2013-02-18 2014-08-21 Vegenics Pty Limited Ligand binding molecules and uses thereof
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
EP2994758B1 (de) 2013-05-08 2017-12-20 Opthea Limited Biomarker für altersbedingte makuladegeneration (amd)
US10203338B2 (en) 2013-05-14 2019-02-12 Siemens Healthcare Diagnostics Inc. Stabilized liquid formulations containing receptors
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
CN103319610B (zh) * 2013-07-05 2016-01-27 华博生物医药技术（上海）有限公司 重组融合蛋白及其制法和用途
KR20230152151A (ko) 2013-07-12 2023-11-02 이베릭 바이오, 인크. 안과적 질환을 치료하거나 예방하기 위한 방법
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
BR112016022345A2 (pt) 2014-03-31 2017-10-10 Genentech Inc terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3169353B1 (de) 2014-07-16 2019-12-18 Sanofi Biotechnology Verfahren zur behandlung von patienten mit heterozygoter familiärer hypercholesterolämie (hefh)
TR201909951T4 (tr) 2014-07-18 2019-07-22 Sanofi Sa Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JP6800141B2 (ja) 2014-08-12 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置
EP3207128B1 (de) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Zwitterionische butyrylcholinesterasepolymerkonjugate
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
WO2016200835A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
RS61532B1 (sr) 2015-07-14 2021-04-29 Bristol Myers Squibb Co Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
KR20180034672A (ko) 2015-08-18 2018-04-04 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
LT4019019T (lt) 2016-05-20 2024-06-25 Biohaven Therapeutics Ltd. Riluzolo, riluzolo provaistų arba riluzolo analogų naudojimas kartu su imunoterapijos rūšimis vėžio formų gydymui
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3568150A4 (de) 2017-01-10 2020-12-02 Xcella Biosciences, Inc. Kombinationstumorbehandlung mit integrin-bindendem fc-fusionsprotein und immunmodulator
KR102667021B1 (ko) 2017-05-06 2024-05-21 리제너론 파아마슈티컬스, 인크. Aplnr 길항제 및 vegf 저해제를 이용한, 안 장애의 치료 방법
EP3694890A4 (de) 2017-10-12 2021-11-03 Immunowake Inc. Leichtkettiges antikörperfusionsprotein mit vegfr
CN111356480A (zh) 2017-10-20 2020-06-30 脉管生物生长有限公司 用于抗血管生成剂疗法的诊断方法
EP3710483A4 (de) * 2017-11-16 2021-10-20 XL-protein GmbH Pasylierte vegfr/pdgfr-fusionsproteine und deren verwendung in der therapie
KR20200112893A (ko) 2018-01-26 2020-10-05 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-vegf 제제를 사용한 혈관신생 장애의 치료 방법 및 조성물
CN113784730A (zh) 2019-03-13 2021-12-10 脉管生物生长有限公司 抗肿瘤疗法的方法
WO2021020979A1 (en) 2019-07-31 2021-02-04 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
EP4058067A1 (de) 2019-11-12 2022-09-21 Oxford BioMedica (UK) Limited Produktionssystem
JP2023502501A (ja) 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼内血管新生のための長時間作用型ｖｅｇｆ阻害剤
PE20221770A1 (es) 2019-12-06 2022-11-11 Regeneron Pharma Composiciones de proteina anti-vegf y metodos para producir la misma
KR20220139911A (ko) 2020-02-13 2022-10-17 옥스포드 바이오메디카(유케이) 리미티드 렌티바이러스 벡터의 생산
EP4118217A1 (de) 2020-03-13 2023-01-18 Oxford BioMedica (UK) Limited Lentivirale vektoren
CA3181779A1 (en) 2020-05-11 2021-11-18 Regeneron Pharmaceuticals, Inc. Viral clearance by low ph hold
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
CA1340456C (en) 1986-07-07 1999-03-23 Hubert J.P. Schoemaker Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
NO873164L (no) 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
EP0266032A1 (de) 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
CA1339445C (en) 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5008196A (en) * 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE69232718T2 (de) * 1991-02-22 2003-04-03 American Cyanamid Co Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
CN1701814A (zh) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
DK0694042T3 (da) * 1993-03-25 2005-02-14 Merck & Co Inc Inhibitor af vaskulær endothelcellevækstfaktor
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
DE69534996T2 (de) * 1994-06-09 2007-05-10 Licentia Oy Monoklonaler antikörper gegen flt4-rezeptor-tyrosin-kinase und dessen verwendung zur diagnose und therapie
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
NZ515913A (en) 1999-06-08 2004-01-30 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
US6683349B1 (en) * 1999-10-29 2004-01-27 Sanyo Electric Co., Ltd. Semiconductor device and method of manufacturing the same
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same

Also Published As

Publication number Publication date
WO1997044453A1 (en) 1997-11-27
EP1666499A2 (de) 2006-06-07
US20110301338A1 (en) 2011-12-08
JP3457330B2 (ja) 2003-10-14
US8268591B2 (en) 2012-09-18
US20110213130A1 (en) 2011-09-01
EP2336322A1 (de) 2011-06-22
US7771721B2 (en) 2010-08-10
CA2804657A1 (en) 1997-11-27
US9273113B2 (en) 2016-03-01
DK0907733T3 (da) 2006-09-18
US20070128695A1 (en) 2007-06-07
EP0907733B1 (de) 2006-05-24
US8268313B2 (en) 2012-09-18
US20110300578A1 (en) 2011-12-08
US20050281831A1 (en) 2005-12-22
EP0907733A1 (de) 1999-04-14
US20110301339A1 (en) 2011-12-08
EP1710254A3 (de) 2007-04-11
EP1710254A2 (de) 2006-10-11
AU717112B2 (en) 2000-03-16
DE69735942T2 (de) 2007-01-04
ATE327327T1 (de) 2006-06-15
AU3060497A (en) 1997-12-09
US20110301337A1 (en) 2011-12-08
US20090010933A1 (en) 2009-01-08
US6100071A (en) 2000-08-08
US20090234103A1 (en) 2009-09-17
US6383486B1 (en) 2002-05-07
US20110300577A1 (en) 2011-12-08
US20030092604A1 (en) 2003-05-15
US5952199A (en) 1999-09-14
US20130178418A1 (en) 2013-07-11
US8273353B2 (en) 2012-09-25
US6897294B2 (en) 2005-05-24
ES2267143T3 (es) 2007-03-01
JP2000502357A (ja) 2000-02-29
CA2253738A1 (en) 1997-11-27
EP1666499A3 (de) 2006-06-21
NZ332779A (en) 1999-06-29

Similar Documents

Publication Publication Date Title
DE69735942D1 (de) Neuartige inhibitoren der aktivität des wachstumsfaktors für gefäss-endothelzellen (vegf), ihre verwendungen und verfahren zu ihrer herstellung
Patel et al. Organization of the fibronectin gene provides evidence for exon shuffling during evolution.
Zou et al. Blood vessel formation in the tissue-engineered bone with the constitutively active form of HIF-1α mediated BMSCs
CA2030518C (en) Osteoinductive compositions
Grotendorst et al. A novel transforming growth factor b response element controls the expression of the connective tissue growth factor gene
Zhu et al. The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin.
US5846770A (en) DNA molecules encoding human chordin
Moscatelli et al. Multiple forms of an angiogenesis factor: basic fibroblast growth factor
JP2004041236A (ja) 骨形成具
IL189573A0 (en) A chimeric polypeptide comprising a vascular endothelial cell growth factor-e (vegf-e) polypeptide fused to a heterologous amino acid sequence
CN1226835A (zh) 用于伤口愈合的体内基因转移
JP2007267741A (ja) ヒトｓｄｆ−５蛋白および組成物
ATE105842T1 (de) Von thrombin abstammende polypeptid- zusammensetzungen und methoden für ihre benutzung.
PT76472A (de) Neue derivate von cycloalka<c>pyrrol-carbonsaeuren verfahren zu ihrer herstellung diese enthaltende mittel und deren verwendung sowie neue cycloalka<c>pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
DE69636720D1 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
JP2008206520A (ja) 骨髄に由来するＴＧＦβ１応答細胞
ATE455852T1 (de) Neues hämopoietin rezeptorprotein nr10
CA2214439C (en) A novel growth factor and a genetic sequence encoding same
Hino et al. cDNA cloning and genomic structure of human bone morphogenetic protein-3B (BMP-3b)
ATE169676T1 (de) Isolierung, charakterisierung und verwendung der menschlichen beta-einheit des immunglobulin e- hochaffinitätsrezeptors
Hamshere et al. The muscle specific domain of mouse N-CAM: structure and alternative splicing patterns
DE69637217D1 (de) Meltrine
DE60042793D1 (de) Inhibitor des hepatozytwachstumsfaktoraktivators und dessen verwendung zur modulation von angiogenese und herzvaskularisierung
EP1591526B1 (de) Frazzled Nukleotidsequenzen, Expressions- produkte, Zusammensetzungen und Verwendungen
Rosenblum et al. Alpha 1-VIII collagen is expressed in the rat glomerulus and in resident glomerular cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition